Nature Biotechnology
- 24, 1515 - 1519 (2006)
doi:10.1038/nbt1206-1515
Moving goalposts—regulatory oversight of antibacterial drugsRandall Brenner, Evelyn J Ellis-Grosse & Roger Echols
Randall Brenner is at Wyeth Pharmaceuticals, 500 Arcolo Road, Collegeville, Pennsylvania 19426, USA, and Evelyn J. Ellis-Grosse (formerly of Wyeth) is at e2g Biopharmaceutical Counseling, 994 Skelp Level Road, Downingtown, Pennsylvania, 19335 USA. Wyeth is a co-sponsor of this focus. Roger Echols is at Replidyne Inc., 1450 Infinite Drive, Louisville, Colorado 80027, USA. brenner1@wyeth.com or evelyn@e2gconsulting.com or rechols@replidyne.com
Is uncertainty concerning the regulation of antimicrobial drug trials stifling investment in infectious disease treatments? Here, experts from a large pharma company and a biotech firm provide their perspectives.
|
